Plasmacytoid urothelial carcinoma is a rare bladder cancer variant with scarce data on outcomes and prognostic factors. We report our institutional experience with this histology to determine response to neoadjuvant chemotherapy, definitive surgery and survival.
(UroToday.com) In this educational session, Dr. Heath discussed the variability in prostate cancer treatments and outcomes based on geographic location and race. Within localized disease, Dr. Heath highlighted data published in 2020 from the National Cancer Database, which includes over 214,000 men diagnosed with high-risk prostate cancer between 2004 and 2016. This disease is typically managed […]
Sam Chang: Hello, everyone. I have the pleasure of introducing two, actually, superstars when it comes to upper tract disease. My name is Sam Chang. I’m a urologist in Nashville and I work at Vanderbilt University. We’re going to focus on the perspective and collaboration between the surgeon and the medical oncologist in a field […]
(UroToday.com) This session was a multidisciplinary case discussion focusing on multiple topics including (1) treatment of BCG unresponsive non-muscle invasive bladder cancer, (2) treatment of muscle-invasive urothelial carcinoma in cisplatin eligible and ineligible patients, (3) the implications of pathologic response to neoadjuvant chemotherapy, (4) the role of adjuvant therapy, (5) the management of metastatic urothelial carcinoma […]
(UroToday.com) Beginning with the introduction of docetaxel for metastatic castration resistant prostate cancer (mCRPC) in 2004, there has been a dramatic and rapid proliferation of systemic therapy options in advanced prostate cancer including a number of novel hormonal therapies (including abiraterone acetate and enzalutamide), second-line chemotherapy (cabazitaxel), bone-targeting agents (radium-223) and other targeted agents (including olaparib, […]
(UroToday.com) This session was a multidisciplinary case discussion focusing on multiple topics including (1) treatment of BCG unresponsive non-muscle invasive bladder cancer, (2) treatment of muscle-invasive urothelial carcinoma in cisplatin eligible and ineligible patients, (3) the implications of pathologic response to neoadjuvant chemotherapy, (4) the role of adjuvant therapy, (5) the management of metastatic urothelial carcinoma […]
(UroToday.com) There has been a dramatic and rapid proliferation of systemic therapy options in advanced prostate cancer since the introduction of docetaxel for metastatic castration resistant prostate cancer (mCRPC) in 2004. These newer treatments have included a number of novel hormonal therapies (including abiraterone acetate and enzalutamide), second-line chemotherapy (cabazitaxel), bone-targeting agents (radium-223), and other targeted […]
(UroToday.com) This session was a multidisciplinary case discussion focusing on multiple topics including (1) treatment of BCG unresponsive non-muscle invasive bladder cancer, (2) treatment of muscle-invasive urothelial carcinoma in cisplatin eligible and ineligible patients, (3) the implications of pathologic response to neoadjuvant chemotherapy, (4) the role of adjuvant therapy, (5) the management of metastatic urothelial […]
Benign prostatic hyperplasia (BPH), frequently affecting elderly men, is associated with bothersome lower urinary tract symptoms (LUTS) and represents a growing nosological entity in terms of health care costs and morbidity. Current pharmacological treatments include 5-α reductase inhibitors, α-adrenergic antagonists, and non-steroidal anti-inflammatory drugs. However, a distinct proportion of patients with LUTS do not respond to treatment and a […]
(UroToday.com) At the metastatic castration resistant prostate cancer (mCRPC) session at the Society of Nuclear Medicine & Molecular Imaging 2021 Annual Meeting, Dr. Daniel Lee discussed osseous molecular radiotherapy for mCRPC. Dr. Lee highlighted that mCRPC is the terminal phase of the disease, with a poor prognosis, encompassing many patients with primarily skeletal disease. Indeed, skeletal […]
